Drug Trial Radar · NCT03623243
Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS Patients
Last checked: Nov 20, 2026Latest source record: Jun 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
185
Actual
Start
Feb 14, 2019
Primary completion
Jul 6, 2022
Study completion Jul 6, 2022
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Aug 9, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To assess safety and tolerability of patients converting from approved Relapsing Multiple Sclerosis (RMS) Disease Modifying Therapies (DMTs) to siponimod.
Conditions
- Multiple Sclerosis
- Relapsing Multiple Sclerosis
- Advancing Multiple Sclerosis
Interventions
SiponimodDrug
Siponimod 2mg tablets taken once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With at Least One Treatment-emergent Adverse Event (TEAE) Related to Study Drug During the Treatment PeriodTime frame: From first dose of study drug up to 30 days after last dose of study drug (up to 7 months)
Locations
55 sites in 2 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Birmingham, Alabama
Novartis Investigative Site
Cullman, Alabama
Alabama Neurology Associates
Homewood, Alabama
Novartis Investigative Site
Tucson, Arizona
Novartis Investigative Site
Fresno, California
Novartis Investigative Site
Fullerton, California
Novartis Investigative Site
Irvine, California
Novartis Investigative Site
Colorado Springs, Colorado
Novartis Investigative Site
Denver, Colorado
Novartis Investigative Site
Fort Collins, Colorado
Novartis Investigative Site
Boca Raton, Florida
Novartis Investigative Site
Bradenton, Florida
MS & Neuromuscular Center of Excellence
Clearwater, Florida
Novartis Investigative Site
Maitland, Florida
Novartis Investigative Site
Miami, Florida
Novartis Investigative Site
Ocala, Florida
Novartis Investigative Site
Oldsmar, Florida
Novartis Investigative Site
Orlando, Florida
Novartis Investigative Site
Ormond Beach, Florida
Novartis Investigative Site
Sarasota, Florida
Novartis Investigative Site
Sunrise, Florida
Novartis Investigative Site
Tampa, Florida
Novartis Investigative Site
Vero Beach, Florida
Novartis Investigative Site
Flossmoor, Illinois
Novartis Investigative Site
Indianapolis, Indiana
Novartis Investigative Site
Lexington, Kentucky
Novartis Investigative Site
Lexington, Kentucky
Novartis Investigative Site
Lexington, Kentucky
Novartis Investigative Site
Rockville, Maryland
Novartis Investigative Site
Clinton Township, Michigan
Novartis Investigative Site
St Louis, Missouri
Novartis Investigative Site
Las Vegas, Nevada
Novartis Investigative Site
Hackensack, New Jersey
Novartis Investigative Site
Asheville, North Carolina
Novartis Investigative Site
Greensboro, North Carolina
Novartis Investigative Site
Raleigh, North Carolina
Novartis Investigative Site
Cincinnati, Ohio
Novartis Investigative Site
Cleveland, Ohio
Novartis Investigative Site
Oklahoma City, Oklahoma
Abington Neurological Associates, Ltd
Abington, Pennsylvania
Showing 40 of 55 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.